MEDraysintell considers 2016 to be the pivotal year for the nuclear medicine industry.

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, June 27, 2016 /EINPresswire.com/ -- MEDraysintell releases its new Nuclear Medicine World Market Report and Directory–Edition 2016, a 990-page document that provides an exhaustive description and analysis of over 370 radiopharmaceuticals and radionuclides with a comprehensive profile of more than 170 companies and institutions active in the radiopharmaceuticals industry.

MEDraysintell estimated the global market for nuclear medicine (radiopharmaceuticals) at US$ 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. While it has been stable last year, this market is expected to climb to US$ 25 billion by 2030. MEDraysintell considers the year 2016 to be the pivotal year in the development of the nuclear medicine industry, shifting from a market centered on radiodiagnostics to a business driven by radiotherapeutics, with a product like Xofigo (Bayer) showing a blockbuster profile and the upcoming launch of new radiotherapeutics with high revenue potential such as Lutathera (Advanced Accelerator Applications). Other radiotherapeutics will penetrate the market later in the decade also labeled with Lu-177. The year 2016 is also the turning point for the introduction of new proprietary fluorinated molecules and novel radiodiagnostics based on Ga-68. Innovative solutions and additional sources will also emerge to cover the need for molybdenum-99. Finally with an increasing interest from the conventional pharmaceutical industry and institutional investors, mergers and acquisitions activity is anticipated to accelerate.

All these topics and much more are extensively covered in the new Nuclear Medicine World Market Report & Directory, Edition 2016. This report has become the sole trusted source of intelligence in this industry. This third edition will once again advice the radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development in this field as well as the potential of merger and acquisitions (M&A).

More information and a table of contents are available at:
http://medraysintell.com/Nuclear_Medicine.html


About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 1,900 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

Paul-Emmanuel Goethals and Richard Zimmermann
MEDraysintell
+32 491 080 968 and +33 6 82 80 06 00
email us here